Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured ...

Given that the Australian government heavily subsidizes pharmaceuticals— spending more than $AU16.7 billion annually through ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been approved for adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express ...

Merck & Co (MSD) has initiated the randomised MOBILIZE-1 Phase III trial to assess the immunogenicity, efficacy, and safety ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

Merck is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is ...

Two new vaccine advisers tapped by Health and Human Services Secretary Robert F. Kennedy Jr. have served as paid expert ...